Chief Legal Officer Chew Jesse covered exercise/tax liability with 42,265 shares, decreasing direct ownership by 11% to 326,824 units (SEC Form 4)

$ARAY
Medical/Dental Instruments
Health Care
Get the next $ARAY alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chew Jesse

(Last) (First) (Middle)
1240 DEMING WAY

(Street)
MADISON 53717

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ACCURAY INC [ ARAY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/29/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/02/2024 F 42,265(1) D $2.15 326,824 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units(2) $0 11/29/2024 A 187,500 (3) (3) Common Stock 187,500 $0 187,500 D
Explanation of Responses:
1. Represents shares of Common Stock that were withheld by the issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of RSUs.
2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
3. The restricted stock units (RSUs) are released at vest. At total of 34% of the shares subject to this grant become vested and are released on the first anniversary of the vesting commencement date and the remaining shares vest and are released at a rate of 33% on the second anniversary and 33% on the third anniversary of the commencement date.
Remarks:
/s/ Jesse Chew 12/03/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ARAY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARAY

DatePrice TargetRatingAnalyst
2/13/2024$9.00Buy
ROTH MKM
6/23/2022$7.50Buy
B. Riley Securities
12/22/2021$7.50Buy
Loop Capital
More analyst ratings

$ARAY
Press Releases

Fastest customizable press release news feed in the world

See more
  • Accuray to Participate at 37th Annual Roth Conference

    MADISON, Wis., March 12, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today announced its participation in the 37th Annual Roth Conference taking place on March 16 -18, 2025 in Dana Point, California. Management will participate in a fireside chat on Tuesday, March 18, 2025, at 9:30am PT / 12:30pm ET, and will be available for one-on-one meetings with investors. A live webcast of the fireside chat can be accessed here and on the Accuray website at investors.accuray.com. The webcast replay of the presentation will be available on the company's website about one hour

    $ARAY
    Medical/Dental Instruments
    Health Care
  • Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance

    MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2024. Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidanceTotal net revenue was $116.2 million, an increase of 8 percent year-over-yearNet income was $2.5 million compared to a net loss of $9.6 million in the prior year periodAdjusted EBITDA was $9.6 million compared to $2.0 million in the prior year period"Our strong Q2 performance reflects outstanding execution of our str

    $ARAY
    Medical/Dental Instruments
    Health Care
  • Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product

    MADISON, Wis., Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture. Shandong Cancer Hospital and Institute was the first hospital in China to receive the new Tomo C System which has already demonstrated its value by expanding clinical capabilities and the opportunity to offer potentially curative treatment to more people diagnosed with cancer. This first cohort of Tomo C System treatments also represent a milestone for Accuray wh

    $ARAY
    Medical/Dental Instruments
    Health Care

$ARAY
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ARAY
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARAY
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARAY
SEC Filings

See more

$ARAY
Leadership Updates

Live Leadership Updates

See more
  • Leonel Peralta to Join Accuray as Chief Operations Officer

    MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has

    $ARAY
    Medical/Dental Instruments
    Health Care
  • Accuray Appoints Michael Murphy as VP, Corporate Controller

    MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024

    $ARAY
    Medical/Dental Instruments
    Health Care
  • Robert C. Kill Joins Accuray Board of Directors

    SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie

    $ARAY
    Medical/Dental Instruments
    Health Care

$ARAY
Financials

Live finance-specific insights

See more
  • Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance

    MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2024. Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidanceTotal net revenue was $116.2 million, an increase of 8 percent year-over-yearNet income was $2.5 million compared to a net loss of $9.6 million in the prior year periodAdjusted EBITDA was $9.6 million compared to $2.0 million in the prior year period"Our strong Q2 performance reflects outstanding execution of our str

    $ARAY
    Medical/Dental Instruments
    Health Care
  • Accuray to Report Second Quarter Fiscal 2025 Financial Results on February 5, 2025

    MADISON, Wis., Jan. 22, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2025, ended December 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 5, 2025. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (interna

    $ARAY
    Medical/Dental Instruments
    Health Care
  • Accuray Reports Fiscal 2025 First Quarter Financial Results

    Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis., Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the first quarter ended September 30, 2024. "We continue to make solid progress in the execution of our strategic growth agenda and performed better than expected in the first quarter and are on track to deliver our fiscal 2025 plan. Our performance in the China region was strong and we saw significant interest in the recently introduced Accuray Tomo® C System and growth in our service business. I could not be mor

    $ARAY
    Medical/Dental Instruments
    Health Care

$ARAY
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more